Company / PP&E (Net)
TherapeuticsMD, Inc. PP&E (Net) History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$78.0K
FY2022
5-year range
$78.0K / $1.9M
FY2018-FY2022
Trend
-93.5%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 3 consecutive years, from $3M in FY2019 to $78,000 in FY2022.
Based on SEC 10-K filings.
$78,000 in FY2022 with a 5-year CAGR of -29.2%.
Declined from $2M to $78,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -68.6%
- 5-Year CAGR
- -29.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- TherapeuticsMD, Inc.'s pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of -29.2%, indicating a declining trend.
- In FY2022, pp&e (net) decreased 93.5% year-over-year.
- Peak pp&e (net) was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $78.0K | -93.5% |
| FY2021 | $1.2M | -38.3% |
| FY2020 | $1.9M | -22.6% |
| FY2019 | $2.5M | +430.5% |
| FY2018 | $472.7K | +8.2% |
| FY2017 | $437.1K | -15.4% |
| FY2016 | $516.8K | +160.3% |
| FY2015 | $198.6K | +213.8% |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026